News
Latest news
CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer

CG Oncology

February 27 2024
CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

CG Oncology

January 30 2024
Cancer drugmaker ArriVent follows on CG’s heels with $175M IPO

Yahoo! Finance

January 26 2024
Cancer drug developer CG Oncology valued at $1.75B in strong IPO debut

Reuters

January 25 2024
Synnovation Therapeutics Launches with $102M Series A Funding

Businesswire

January 24 2024
CG Oncology Receives Both FDA Fast Track and Breakthrough Therapy Designation for Cretostimogene Grenadenorepvec in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

CG Oncology

December 05 2023

Get In Touch

Contact Us